ClinicalTrials.gg
Active, not recruitingNCT05730699AQUARELLEUpdated Nov 7, 2024

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

A Phase 3 interventional study of divozilimab in Neuromyelitis Optica Spectrum Disorders, sponsored by Biocad. Active, not recruiting at 19 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study the efficacy and safety of BCD-132 (divozilimab) in subjects with neuromyelitis optica spectrum disorders (NMOSD).

Read the detailed description

BCD-132-6/AQUARELLE is an open-label phase 3 clinical study in subjects with NMOSD. Approximately 105 subjects will be enrolled.

The study consists of a screening period, a treatment period and a follow-up period. During treatment period, the subjects will receive the investigational product divozilimab.

The duration of participation for each subject will be approximately 104 weeks.

02

Conditions studied

  • Neuromyelitis Optica Spectrum Disorders

Browse trials for

03

In context

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

This study's planned enrollment of 105 is above the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.

Browse Neuromyelitis Optica studies →

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NMOSD diagnosed based on the 2015 NMOSD International Consensus Diagnostic Criteria
  • Documented evidence of at least 1 relapse within 12 months before signing the form, or 2 relapses within 24 months before signing the informed consent form
  • A total EDSS score of ≤ 7
  • Presence of IgG antibodies to the Varicella Zoster virus at screening
  • A CD19+ cell proportion of ≥ 1 % of the total lymphocyte count in patients exposed to other anti-B-cell therapies more than 6 months before signing the informed consent form

Exclusion criteria

Exclusion Criteria:

  • A relapse occurring less than 30 days before signing the form or at screening (patients may be re-screened)
  • Intrathecal oligoclonal or monoclonal IgG production (in patients who are anti-AQP4 seronegative)
  • Other nervous system disorders (including multiple sclerosis) that can mask or affect the assessment of NMOSD symptoms
  • History of other diseases requiring therapy
  • Prior exposure to: alemtuzumab, total lymphatic irradiation, bone marrow transplantation; anti-B-cell therapy drugs, abatacept, satralizumab within 6 months prior to signing the informed consent form; mitoxantrone, cyclophosphamide, methotrexate, cyclosporine A, tacrolimus, eculizumab, tocilizumab, natalizumab, interferon beta, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate within 3 months before signing the informed consent form; immunoglobulin products within 30 days before signing the informed consent form; transfusion of blood or blood components within 30 days before signing the informed consent form; systemic at the time of signing the informed consent form
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    BCD-132 (divozilimab)

    Intravenous infusion of BCD-132 every 24 weeks

    Biological: divozilimab

Interventions

06

What researchers measure

Primary outcomes

  1. Adjudicated annualized relapse rate [Week 24]

    Adjudicated annualized relapse rate

    Time frame: Week 24

Secondary outcomes

  1. Time to the first adjudicated relapse

    Time to the first adjudicated relapse is defined as the time from the date of randomization in the study to the date of the onset of symptoms of the adjudicated relapse. Each relapse will be adjudicated by an independent neurological commission

    Time frame: Week 100

  2. Adjudicated annualized relapse rate

    Adjudicated annualized relapse rate

    Time frame: Week 52, 100

  3. Proportion of subjects without adjudicated relapses

    Proportion of subjects without adjudicated relapses at week 24, 52, 100

    Time frame: Weeks 24, 52, 100

  4. Change in the Expanded Disability Status Scale (EDSS) score

    Change in the Expanded Disability Status Scale (EDSS) at week 24, 52, 100 relative to baseline.The EDSS ranges from 0 to 10. An increase in EDSS values corresponds to a worsening disability.

    Time frame: Week 24, 52, 100

  5. Proportion of subjects with confirmed increase in disability

    Confirmed increase in disability is defined as an increase in the EDSS score (not related to a previous relapse and assuming there is no relapse at assessment) compared to Day 1 (baseline) by at least 1.5 in subjects with a baseline score of 0; by at least 1.0 in subjects with a baseline score of \> 0 and ≤ 5.5; and by at least 0.5 in subjects with a baseline score of ≥ 6.0 persisting for ≥ 3 months

    Time frame: Weeks 24, 26, 48, 52, 100

  6. Vision acuity change

    Vision acuity change at Week 24, 52, 100 relative to baseline

    Time frame: Week 24, 52, 100

  7. Change in the Timed 25-Foot (7.62 m) Walk (T25-FW) test

    Change in the Timed 25-Foot (7.62 m) Walk (T25-FW) test over time compared to baseline. T25-FW test is a way to quantify lower limb functions. The subject standing at one end of a clearly marked 25-foot (7.62-meter) course is asked to walk the distance as quickly but as safely as possible. After the first attempt, the subject is asked to walk the same distance again. The results (time in seconds) of both attempts are recorded.

    Time frame: Up to Week 100

  8. Changes in the severity of pain using a Numeric Rating Scale

    Changes in the severity of pain at Week 4, 24, 52, 100 relative to baseline. The Numerical Rating Scale (NRS) will be used to assess the intensity of the subject's pain. NRS consists of consecutive numbers from 0 to 10, where 0 is no pain and 10 is the most severe pain that can be imagined.

    Time frame: Week 4, 24, 52, 100

  9. Change in the quality of life using a SF-36

    Change in the quality of life parameters using a SF-36 questionnaire at week 24, 52, 100 relative to baseline. SF-36 (Short Form-36) questionnaire includes a total of 36 questions.

    Time frame: Week 24, 52, 100

  10. CUA

    CUA (Cumulative Total Active) - • Cumulative number of new Gd-enhancing T1-weighted lesions and new T2-weighted lesions or enlarging T2-weighted lesions without double counting

    Time frame: Week 24

07

Study locations

19 sites
  • Llc "Profimed"
    Barnaul, Russian Federation
  • Municipal Autonomous Healthcare Institution of the Order of the Red Banner of Labor "City Clinical Hospital No.1"
    Chelyabinsk, Russian Federation
  • Regional Clinical Hospital No.3
    Chelyabinsk, Russian Federation
  • Kuzbass Clinical Hospital named after S.V. Belyaev
    Kemerovo, Russian Federation
  • Khanty-Mansiysk autonomous district - Ugra "The district clinical hospital"
    Khanty-Mansiysk, Russian Federation
  • Center for Cardiology and Neurology
    Kirov, Russian Federation
  • Regional Clinical Hospital № 1 named after Professor S. V. Ochapovsky
    Krasnodar, Russian Federation
  • Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI)
    Moscow, Russian Federation
  • Semashko Regional Clinical Hospital
    Nischni Nowgorod, Russian Federation
  • LLC "Medis"
    Nizhny Novgorod, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, Russian Federation
  • Pyatigorsk City Clinical Hospital No.2
    Pyatigorsk, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University"
    Rostov-on-Don, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    Saint Petersburg, Russian Federation
  • Seredavin Regional Clinical Hospital
    Samara, Russian Federation
  • Republican Clinical Hospital No.4
    Saransk, Russian Federation
  • Siberian State Medical University
    Tomsk, Russian Federation
  • Medical and Sanitary Unit "Neftyanik"
    Tyumen, Russian Federation
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Jan 2025, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Feb 16, 2023
StartActual
Dec 12, 2022
Primary completionEst.
Jan 2025
CompletionEst.
Sep 2026
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05730699
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Dec 12, 2022
Primary completion
Jan 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 7, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divozilimab

Start the discussion